Global Chronic Obstructive Pulmonary Disease Drugs Market 2026-2030
상품코드:1937204
리서치사:TechNavio
발행일:2026년 02월
페이지 정보:영문 306 Pages
라이선스 & 가격 (부가세 별도)
ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
한글목차
세계의 만성폐쇄성폐질환(COPD) 치료제 시장은 2025년부터 2030년까지 79억 4,330만 달러 증가하고, 예측 기간 동안 CAGR은 6.2%로 예측됩니다. 세계의 COPD 치료제 시장에 관한 종합적인 분석, 시장 규모와 예측, 동향, 성장 촉진요인, 과제 및 약 25개 벤더 분석을 제공합니다.
본 보고서는 현재 시장 상황, 최신 동향 및 촉진요인, 시장 환경 전반에 대한 최신 분석을 제공합니다. COPD 유병률 증가, 강력한 파이프라인과 신약 승인, 고정용량 제제에 대한 수요 증가가 시장을 주도하고 있습니다.
이번 조사는 업계 주요 관계자들의 정보를 포함한 1차 정보와 2차 정보의 객관적인 조합을 통해 이루어졌습니다. 이 보고서에는 주요 기업 분석과 함께 종합적인 시장 규모 데이터, 지역별 분석과 함께 부문 및 공급업체 현황이 포함되어 있습니다. 보고서에는 과거 데이터와 예측 데이터가 수록되어 있습니다.
시장 범위
기준 연도
2026년
종료 연도
2030년
예측 기간
2026-2030년
성장 모멘텀
가속
전년비 2026년
5.9%
CAGR
6.2%
증가액
79억 4,330만 달러
이 보고서는 향후 몇 년 동안 세계 만성폐쇄성폐질환(COPD) 치료제 시장의 성장을 견인할 주요 요인 중 하나로 치료 접근법에 대한 연구 확대가 꼽혔습니다. 또한, 약물전달 기기의 발전과 흡입 요법의 확대로 인해 시장에서 상당한 수요가 예상됩니다.
목차
제1장 주요 요약
제2장 Technavio 분석
제3장 시장 구도
제4장 시장 규모
제5장 시장 규모 실적
제6장 정성 분석
제7장 Five Forces 분석
제8장 시장 세분화 : 제품별
제9장 시장 세분화 : 유통 채널별
제10장 시장 세분화 : 투여 경로별
제11장 시장 세분화 : 질환 유형별
제12장 고객 상황
제13장 지역별 상황
제14장 촉진요인, 과제, 기회
제15장 경쟁 구도
제16장 경쟁 분석
제17장 부록
KSM
영문 목차
영문목차
The global chronic obstructive pulmonary disease drugs market is forecasted to grow by USD 7943.3 mn during 2025-2030, accelerating at a CAGR of 6.2% during the forecast period. The report on the global chronic obstructive pulmonary disease drugs market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.
The report offers an up-to-date analysis regarding the current market scenario, the latest trends and drivers, and the overall market environment. The market is driven by rising prevalence of copd, strong pipeline and new drug approvals, growing demand for fixed-dose combinations.
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market size data, segment with regional analysis and vendor landscape in addition to an analysis of the key companies. Reports have historic and forecast data.
Market Scope
Base Year
2026
End Year
2030
Series Year
2026-2030
Growth Momentum
Accelerate
YOY 2026
5.9%
CAGR
6.2%
Incremental Value
$7943.3 mn
Technavio's global chronic obstructive pulmonary disease drugs market is segmented as below:
By Product
Combination therapy
Monotherapy
By Distribution Channel
Hospital pharmacies
Retail pharmacies
Online pharmacies
By Route Of Administration
Inhalation
Oral
Injectable
By Disease Type
Chronic bronchitis
Emphysema
Geography
North America
US
Canada
Mexico
Europe
Germany
UK
France
Italy
Russia
The Netherlands
Spain
Asia
Rest of World (ROW)
Rest of World (ROW)
This study identifies the expanding research in curative approaches as one of the prime reasons driving the global chronic obstructive pulmonary disease drugs market growth during the next few years. Also, advances in drug delivery devices and rising expansion of inhalation therapies will lead to sizable demand in the market.
The report on the global chronic obstructive pulmonary disease drugs market covers the following areas:
Global chronic obstructive pulmonary disease drugs market sizing
Global chronic obstructive pulmonary disease drugs market forecast
Global chronic obstructive pulmonary disease drugs market industry analysis
The robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading global chronic obstructive pulmonary disease drugs market vendors that include AstraZeneca Plc, Boehringer Ingelheim GmbH, Cadila Pharmaceuticals Ltd., CHIESI Farmaceutici SpA, Cipla Inc., Exela Pharma Sciences LLC, GlaxoSmithKline Plc, Glenmark Pharmaceuticals Ltd., Innoviva Inc., Lupin Ltd., Merck and Co. Inc., Mundipharma International Ltd., Novartis AG, Philip Morris International, SHIONOGI Co. Ltd., Sumitomo Pharma Co. Ltd., Teva Pharmaceutical Ltd., Theravance Biopharma Inc., Vertex Pharmaceuticals Inc., Viatris Inc.. Also, the global chronic obstructive pulmonary disease drugs market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage all forthcoming growth opportunities.
The publisher presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive primary and secondary research. The market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast accurate market growth.
Table of Contents
1 Executive Summary
1.1 Market overview
Executive Summary - Chart on Market Overview
Executive Summary - Data Table on Market Overview
Executive Summary - Chart on Global Market Characteristics
Executive Summary - Chart on Market by Geography
Executive Summary - Chart on Market Segmentation by Product
Executive Summary - Chart on Market Segmentation by Distribution Channel
Executive Summary - Chart on Market Segmentation by Route of Administration
Executive Summary - Chart on Market Segmentation by Disease Type
Executive Summary - Chart on Incremental Growth
Executive Summary - Data Table on Incremental Growth
Executive Summary - Chart on Company Market Positioning
2 Technavio Analysis
2.1 Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria
Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria
2.2 Criticality of inputs and Factors of differentiation
